

AEROSIL® and AEROPERL®

Pharma Colloidal Silicon Dioxide Products



CONTENTS

1. AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide – the optimal glidant and beyond	3
2. Manufacture of AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide	6
2.1 Flame hydrolysis	6
2.2 Hydrophobic post-treatment	7
2.3 Densification	8
2.4 Granulation	9
3. AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide: the difference to other silicon dioxide types	10
4. Product safety and regulatory information	11
4.1 Product safety information	12
4.2 Pharmaceutical regulatory status	12
4.3 Other regulatory topics	12
4.4 Microbial contamination	12
4.5 Packaging and storage	13
4.6 Handling	13

¹ This brochure uses the term “colloidal silicon dioxide” in the sense of the USP/NF monograph for silica products produced by flame hydrolysis. Products of this kind are also known as fumed silica in other industries. The products are not to be mistaken as “colloidal silica” or “silica sol” which stands for dispersions of spherical silica particles in a fluid (typically water). For an overview of the different forms of silica please refer to the chapter “Silica” in Ullmann’s Encyclopedia of Industrial Chemistry, Wiley and Sons.

1. AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide – the optimal glidant and beyond

AEROSIL® colloidal silicon dioxide¹ has been used as a pharmaceutical excipient^{1,2} since the early days of direct compression tableting⁴. AEROSIL® 200 Pharma is the traditional glidant, helping to obtain the optimal powder flow required by today’s high speed tablet presses. Since the time that AEROSIL® 200 Pharma was first used as a glidant, challenges in formulating solid dosage forms have become more complex. Tablet powders of different average particle size, composition and moisture sensitivity are common in the industry – requiring specialized products to be able to compete in an increasingly cost sensitive health care environment. To support the industry in coping with these challenges, Evonik has introduced AEROSIL® and AEROPERL® Pharma colloidal silicon dioxides to the market not only to provide optimal glidants for almost any tableting process, including continuous manufacturing setups, but also to help the pharmaceutical industry with other formulation challenges such as:

- implementing more efficient or economical granulation processes
- incorporating liquids or solutions into solid dosage forms (e.g., liquid or dissolved actives)
- controlling the rheology and helping to stabilize semisolid dosage forms against thermal degradation
- facilitating 3D printing technologies by improving powder flow or rheological properties
- enhancing the dissolution of poorly soluble active pharmaceutical ingredients.



TABLE 1 Physico-chemical properties and pharmacopoeia compliance of AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide

		AEROSIL® 200 Pharma	AEROSIL® 200 VV Pharma	AEROSIL® 300 Pharma	AEROSIL® R 972 Pharma	AEROPERL® 300 Pharma
Characteristics	Type	Powder	Densified powder	Powder	Powder	Granulate
	Behavior in water	Hydrophilic	Hydrophilic	Hydrophilic	Hydrophobic	Hydrophilic
Typical physico-chemical data	Specific surface area (BET, in m²/g)	175 – 225	175 – 225	270 – 330	90 – 130	260 – 320
	Tamped density (in g/L)	Appr. 50	Appr. 120	Appr. 50	Appr. 50	Appr. 270
	pH	3.5 – 5.5	3.5 – 5.5	3.5 – 5.5	-	3.5 – 5.5
Pharmacopoeia compliance	Europe (Ph. Eur.)	Silica, colloidal anhydrous	Silica, colloidal anhydrous	Silica, colloidal anhydrous	Silica, hydrophobic colloidal	Silica, colloidal anhydrous
	USP/NF	Colloidal silicon dioxide	Colloidal silicon dioxide	Colloidal silicon dioxide	Hydrophobic colloidal silica	Colloidal silicon dioxide
	JP	Light anhydrous silicic acid	-	-	-**	-
	China (ChP)	Colloidal silicon dioxide* (Jiaotai Eryanghuagui)	Colloidal silicon dioxide* (Jiaotai Eryanghuagui)	Colloidal silicon dioxide* (Jiaotai Eryanghuagui)	Hydrophobic Colloidal silicon dioxide* (Shushui xing Jiaotai Eryanghuagui)	Colloidal silicon dioxide* (Jiaotai Eryanghuagui)
	India (IP)	Colloidal silicon dioxide	-	-	-	-

* Chinese Pharmacopoeia values are not included on the certificates of analysis. However, AEROSIL® 200 Pharma complies with the quality requirements set forth in monograph "colloidal silicon dioxide" (Jiaotai Eryanghuagui)

** There is no monograph for a hydrophobic silica in JP. The material fulfills all tests in the JP.

TABLE 1 gives an overview of all AEROSIL® and AEROPERL® Pharma products with their characteristics, physico-chemical data and their compliance to the different pharmacopoeia monographs.

AEROSIL® 200 Pharma is and remains the traditional and most popular glidant for solid dosage forms which has set the standard in the industry. The powder has a high specific surface area, is hydrophilic, inert and features universal pharmacopoeia compliance.

In cases where storage space and handling of a low-density powder is a challenge, we recommend **AEROSIL® 200 VV Pharma**. The product has the same physico-chemical parameters as AEROSIL® 200 Pharma but due to a special production step (described in chapter 2.3) possesses twice the density. Storage of the same amount of AEROSIL® 200 VV Pharma compared to AEROSIL® 200 Pharma only requires about half of the floor space. The higher density of the material also results in more favorable powder handling properties, including reduced dust generation.

Compared to the standard glidant, **AEROSIL® 300 Pharma** features a higher specific surface area. This special property leads to an increased surface interaction, making it an even more potent glidant than the industry standard. AEROSIL® 300 Pharma is a very efficient thickener for oils of low polarity.

TABLE 2 AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide applications

Dosage forms	Applications	Products
Solid dosage forms <ul style="list-style-type: none">tabletscapsules	Glidants <ul style="list-style-type: none">Assisting powder flowPreventing powder cakingOptimizing tablet weight uniformityImproving mechanical tablet stability	AEROSIL® 200 Pharma AEROSIL® 200 VV Pharma AEROSIL® 300 Pharma AEROSIL® R 972 Pharma
	Carrier <ul style="list-style-type: none">Cost optimization of granulationsIncorporation of liquids and solutionsImproving dissolution of poorly soluble active pharmaceutical ingredients	AEROPERL® 300 Pharma
Semisolid dosage forms <ul style="list-style-type: none">Gels, ointments, salvesTransdermal therapy systemsSuppositories	Rheology control <ul style="list-style-type: none">Viscosity adjustmentStabilization of dispersionsHeat stabilization of suppositories	AEROSIL® 200 Pharma AEROSIL® 300 Pharma AEROSIL® R 972 Pharma
	Surface effects <ul style="list-style-type: none">Stabilization of emulsions	AEROSIL® R 972 Pharma

TABLE 2 introduces some typical uses of AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide in pharmaceutical formulations

AEROSIL® R 972 Pharma is different from the aforementioned products as it is surface modified, and thereby rendered hydrophobic. The hydrophobic nature of the material is achieved by the irreversible anchoring of organic dimethylsilyl groups on the surface. The surface modification makes the material better compatible with oils in semi-solid dosage forms and can help to protect moisture sensitive or hygroscopic actives in tablets and capsules.

Unlike the powdered AEROSIL® Pharma products **AEROPERL® 300 Pharma** is a granulated version having a high density in the range of 270 g/L. AEROPERL® 300 Pharma features mesoporous granular particles with a median particle size at roughly 40 µm. The granulate due to its porosity is an excellent inert pharmaceutical absorbent, supporting increased solubility.

Table 2 introduces some typical uses of AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide in pharmaceutical formulations. The wide field of applications for AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide, however, is not covered in this brochure but is the topic of more specialized Technical Information brochures that are available from the webpage.




2. Manufacture of AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide

All AEROSIL® and AEROPERL® Pharma products are based on a continuous gas phase, flame hydrolysis process. Starting from the material produced in this process AEROSIL® 200 VV Pharma (densification), AEROSIL® R 972 Pharma (hydrophobic post-treatment) and AEROPERL® 300 Pharma (granulation) are generated in consecutive steps to create their specific product properties.

2.1 FLAME HYDROLYSIS

AEROSIL® Pharma colloidal silicon dioxide is manufactured by the hydrolysis of silicon tetrachloride in a hydrogen oxygen flame according to the following overall chemical reaction:




During the manufacture of AEROSIL® Pharma colloidal silicon dioxide, vaporized silicon tetrachloride is hydrolyzed with very hot steam formed by a hydrogen oxygen flame. The reaction results in the formation of AEROSIL® Pharma fumed silica particles and hydrogen chloride gas as a by-product. AEROSIL® Pharma colloidal silicon dioxide is deacidified and separated from the gaseous by-products. The process, which is described in more detail in **FIGURE 3**, uses exceptionally pure raw materials of exclusively inorganic nature. Neither metal catalysts, organic solvents nor materials of natural or biogenic origin are used, producing an exceptionally pure amorphous powder with a silicon dioxide content of more than 99.8% by weight (based on


the dried substance). The elemental impurity content of the material is below the threshold values given in table A2.2 for Option 1 of the ICH Q3D Guideline⁵ and the pharmacopoeia requirements based on it. Due to the high chemical purity AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide features good compatibility even with active pharmaceutical ingredients having a high sensitivity to heavy metals.

FIGURE 4 shows the particle structure of AEROSIL® Pharma colloidal silicon dioxide. The material features aggregates as the smallest units. These aggregates form agglomerates that are held together by van der Waals and hydrogen bonds. Due to the comparatively weak forces that hold together the agglomerates de-agglomeration occurs when AEROSIL® Pharma colloidal silicon dioxide is mixed with other powders or dispersed in liquid matrices. This de-agglomeration will ultimately lead to free aggregates as the smallest units of the material being are visible in electron microscopy pictures of AEROSIL® Pharma colloidal silicon dioxide do not exist separated from each other but are bound together by covalent bonds to form aggregates. However, the particle size given in the European Pharmacopoeia monograph "Silica, Colloidal Anhydrous" refers to the approximate size of these primary particles. Siloxane and silanol groups cover the surface of hydrophilic AEROSIL® Pharma colloidal silicon dioxide. The silanol groups are responsible for the high affinity of the material for water and polar compounds. Hydrophilic AEROSIL® Pharma colloidal silicon dioxide can adsorb considerable quantities of water without any change in its state of aggregation.

FIGURE 4 Structure of AEROSIL® PHARMA colloidal silicon dioxide



Transmission electron microscopy image of AEROSIL® 200 Pharma obtained after dispersing the material by ultrasound in isopropanol/water.



A graphic model of AEROSIL® silicon dioxide agglomerates

FIGURE 5 Reactions of the surface modification to produce AEROSIL® R 972 PHARMA






FIGURE 3
Flame Hydrolysis Process

FIGURE 6 Water absorption isotherm of AEROSIL® 200 PHARMA and AEROSIL® R 972 PHARMA



Experimental: samples were contacted with gas streams of water activity $aw = 0,03$ to $aw 0,95$ a flow rate of 80 ml/min at 25 °C.

2.2 HYDROPHOBIC POST-TREATMENT

To produce hydrophobic AEROSIL® R 972 Pharma, hydrophilic colloidal silicon dioxide is reacted with dimethyldichlorosilane in a consecutive reaction step that follows immediately after the generation of silica particles in flame hydrolysis (**FIGURE 5**). This step is also conducted at high temperature. As a result, dimethylsilyl groups are irreversibly covalently bound to the surface of the colloidal silicon dioxide particles by very stable siloxane bonds, resulting in a product that neither mixes with water nor absorbs water from the atmosphere (**FIGURE 6**). The hydrophobic treatment also reduces the silanol group density at the surface of the silica.

2.3 DENSIFICATION

AEROSIL® Pharma agglomerates are irregular in size and shape and do not pack well. The considerable amount of void space between the agglomerates is responsible for the low density of traditional colloidal silicon dioxide.

AEROSIL® 200 VV Pharma is a densified grade. Using a purely mechanical densification technology, air is removed from between the agglomerates. The result is larger, more stable, secondary agglomerates that produce considerably less fine dust (particles < 10 - 20 µm in size) than traditional non- densified colloidal silicon dioxide. Due to the purely physical nature of the densification the typical physico-chemical properties such as specific surface area are not affected. The only difference of the two products is the tapped density, which for AEROSIL® 200 VV Pharma is about 120 g/L compared to 50 g/L for the non-densified AEROSIL® 200 Pharma. ^{6, 7}

2.4 GRANULATION

By processing, AEROSIL® Pharma powder can be transformed into round shaped granules with high porosity (**FIGURE 7**). The granulate AEROPERL® 300 Pharma has an average particle size between 20 and 60 µm and is highly porous, with pores predominantly in the mesoporous range between 2 and 50 nm (**FIGURE 8**). The material has a very high tapped density of approximately 270 g/L unmatched by any AEROSIL® Pharma product. The round particle shape imparts exceptional powder flow to the granules. ^{8, 9}

Due to its unique physico-chemical properties AEROPERL® 300 Pharma is a highly effective absorbent and carrier for a multitude of different applications.

FIGURE 7 Scanning electron microscopy (SEM) image of AEROPERL® 300 PHARMA






FIGURE 8 Porosity of AEROPERL® 300 PHARMA



3. AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide: the difference to other silicon dioxide types

Silica produced by flame hydrolysis such as AEROSIL® and AEROPERL® are tested against the regulatory quality requirements of monographs “Colloidal Silicon Dioxide” (USP/NF), “Silica, Colloidal Anhydrous” (Ph. Eur., monograph 434), “Light Anhydrous Silicic Acid” (JP) and “Colloidal Silicon Dioxide” (IP).

Only the AEROSIL® and AEROPERL® fumed silica products identified by the suffix “Pharma” are manufactured according to the International Pharmaceutical Excipients Council (IPEC) GMP guidelines for pharmaceutical excipients. Full traceability of all raw materials and production conditions and stringent observance of hygiene protocols during bag filling are guaranteed. Only for the products identified as “Pharma”, the quality is checked against the requirements of the main pharmacopoeia and certified by appropriate certificates of analysis. Regulatory and technical support for topics typical for pharmaceuticals are only available for products identified as “Pharma”.



4. Product safety and regulatory information

AEROSIL® Pharma colloidal silicon dioxide has been safely used as a pharmaceutical excipient for over 40 years. Current good manufacturing practices as defined for inert pharmaceutical excipients by International Pharmaceutical Excipients Council (IPEC) are followed during the production of AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide. As for all excipients, however, it is the ultimate responsibility of the pharmaceutical manufacturer to determine the suitability of AEROSIL® or AEROPERL® Pharma colloidal silicon dioxide as an excipient in a particular formulation.

Table 3 Toxicological data for hydrophobic AEROSIL® R 972 Pharma

Test	Result
Acute oral toxicity, rat	LD50 > 5.000 mg/kg bw
Acute inhalation toxicity, rat	LC ₀ = 0.477 mg/l/4 h (maximum attainable concentration in air). No death occurred
Eye irritation, rabbit	not irritating
Skin irritation, rabbit	not irritating
Genotoxicity (in vitro)	No evidence of genotoxic potential
Repeated dose toxicity	No significant toxicity
Carcinogenicity	No evidence of carcinogenic potential
Reproductive toxicity	No findings
Human experience	Silicosis or other substance related illnesses were not observed

Table 4 Toxicological data for hydrophilic AEROSIL® 200 Pharma, AEROSIL® 200 VV Pharma, AEROSIL® 300 Pharma and AEROPERL® 300 Pharma

Test	Result
Acute oral toxicity, rat	LD50 > 10.000 mg/kg
Acute inhalation toxicity, rat	LC ₀ = 0.139 mg/l/4 h (maximum attainable concentration in air). No death occurred
Acute dermal toxicity, rabbit	LD50 > 5.000 mg/kg bw
Eye irritation, rabbit	not irritating
Skin irritation, rabbit	not irritating
Genotoxicity (in vitro/in vivo)	No evidence of genotoxic potential
Repeated dose toxicity	No significant toxicity
Carcinogenicity	No evidence of carcinogenic potential
Reproductive toxicity	No findings
Human experience	Silicosis or other substance related illnesses were not observed

TABLE 5 Compendial compliance of pharmaceutical grade AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide products

Product	Tapped Density (in g/L)	Important Pharmacopoeia Monographs Fulfilled	Comments
AEROSIL® 200 Pharma	approx. 50	<ul style="list-style-type: none">Silica, Colloidal Anhydrous (Ph. Eur.)Colloidal Silicon Dioxide (USP/NF)Light Anhydrous Silicic Acid (JP)Colloidal Silicon Dioxide (IP)	
AEROSIL® 200 VV Pharma	approx. 120	<ul style="list-style-type: none">Silica, Colloidal Anhydrous (Ph. Eur.)Colloidal Silicon Dioxide (USP/NF)	Generally fulfills JP except for the volume test. No JP or JPE testing is performed
AEROSIL® 300 Pharma	approx. 50	<ul style="list-style-type: none">Silica, Colloidal Anhydrous (Ph. Eur.)Colloidal Silicon Dioxide (USP/NF)	
AEROSIL® R 972 Pharma	approx. 50	<ul style="list-style-type: none">Silica, Hydrophobic Colloidal (Ph. Eur.)Hydrophobic Colloidal Silica (USP/NF)	No JP monograph for hydrophobic silica exists at this time
AEROPERL® 300 Pharma	approx. 270	<ul style="list-style-type: none">Silica, Colloidal Anhydrous (Ph. Eur.)Colloidal Silicon Dioxide (USP/NF)	Generally fulfills JP except for the volume test. No JP or JPE testing is performed

4.1 PRODUCT SAFETY INFORMATION

AEROSIL® Pharma colloidal silicon dioxide is not harmful when administered orally or topically. It is not irritating to skin and eyes and is unlikely to be absorbed from the gastrointestinal tract in significant amounts. However, it should not be administered parenterally, because untoward tissue reactions or the formation of granulomas could occur¹⁰. Unlike crystalline silica, synthetic amorphous AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide does not cause silicosis. However, it is not recommended for drug delivery by inhalation. AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide is inert toward most active drug ingredients and excipients. Adsorption of active components is possible; however, the amounts are typically low, and the process is reversible.¹¹ The surface modification process of the hydrophobic AEROSIL® R 972 Pharma (see Section 2.2) does not affect the toxicological properties of the parent silica significantly.

Before working with any product, read its Safety Data Sheet carefully. Safety Data Sheets (also known as SDS) for AEROSIL® Pharma products are available for many countries and in different languages. Safety data sheets are available from your local Evonik customer service representative via the respective links in chapter References.

4.2 PHARMACEUTICAL COMPLIANCE

TABLE 5 lists the compendial compliance of all AEROSIL® and AEROPERL® Pharma pharmaceutical grade products.

4.3 OTHER REGULATORY TOPICS

AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide is completely inorganic in nature. The production process does not involve plant or animal based raw materials, nor does it involve organic solvents. Standard statements are available on request containing information on BSE/TSE, GMO as well as on other criteria.

Kosher and Halal Certificates are available upon request; please contact us.



4.4 MICROBIAL CONTAMINATION

Because of the high production temperatures, all AEROSIL® Pharma colloidal silicon dioxide products are sterile immediately after manufacture. It has been reported in the literature that AEROSIL® Pharma colloidal silicon dioxide is not a source of microbial nutrition and that both gram-negative and gram-positive bacteria are unable to survive on dry AEROSIL® Pharma colloidal silicon dioxide for more than hours to days, depending on the type of bacteria.¹² The possible survival of some sporogenic microorganisms cannot be completely ruled out even under these conditions.

The pharmaceutical grades are packaged and stored in accordance with IPEC’s GMP guidelines for bulk pharmaceutical excipients. Microbiological testing is performed on random samples at regular intervals. Full pallets are shrink-wrapped to prevent contamination. We, and our partners along the logistics chain, do all that we can to ensure that AEROSIL® Pharma colloidal silicon dioxide reaches our customers without contamination. However, the unexpected can occur during shipping and storage so we recommend customers perform microbiological checks on the product before using it.

4.5 PACKAGING AND STORAGE

AEROSIL® Pharma colloidal silicon dioxide is packed in multiply paper bags. It is shipped as full pallets, shrink-wrapped at the factory. AEROSIL® Pharma colloidal silicon dioxide is available in FIBC (flexible intermediate bulk container) as well.

AEROPERL® Pharma colloidal silicon dioxide is packaged in multiply bags made from PE-film and paper. The bags are then packed and shipped in a cardboard box on a pallet.

AEROSIL® and AEROPERL® Pharma are chemically stable silicon dioxides that could theoretically be stored for many years without any change in their composition. However, because of their large specific surface area they can adsorb volatile substances and moisture from the environment. Proper storage is critical to prevent external contamination of the bags (for example through dust, dirt, or mold). Bags should be inspected thoroughly before opening to prevent contamination of the product.

We recommend that AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide be stored in a dry place (e.g. 20 °C; 40% rH), in sealed containers protected from volatile substances, and that they be used within two years after its date of manufacture. We also recommend that the shrink wrapping not be completely removed from the pallet, but that an opening be cut to remove only those bags immediately required, and that the opening be resealed.

4.6 HANDLING

Evonik has a team of engineers dedicated to improving the handling of AEROSIL® and AEROPERL® Pharma colloidal silicon dioxide in our customers’ facilities. With proper equipment AEROSIL® and AEROPERL® Pharma products can be handled almost completely dust-free. For more information on these services, please find relevant information on our webpage <https://www.silica-specialist.com/en/service-center/Handling>

Even though AEROSIL® and AEROPERL® colloidal silicon dioxide are inert and non-toxic material, there are certain precautions that we recommend because, although not required, they improve the comfort level of persons working with it:

- The work area should be properly ventilated. In the laboratory, work with AEROSIL® and AEROPERL® Pharma products in a fume cupboard. Where ventilation is not available, a dust respirator is recommended at higher concentrations.
- Avoid continued excessive inhalation by using personal protective equipment.
- Wear appropriate eye protection.
- Wash hands after handling AEROSIL® and AEROPERL® Pharma products as the product may leave a dry feeling on the skin. Use of protective skin cream and/or gloves is recommended when working with AEROSIL® and AEROPERL® products.

See the Safety Data Sheet for information relevant to maximum work area concentrations and other safety aspects of our products. In addition, for safety reasons it should be noted that all dry powders such as AEROSIL® and AEROPERL® colloidal silicon dioxide can build up static electrical charges when subjected to friction during conveyance and/or mixing. When handling AEROSIL® colloidal silicon dioxide near flammable or explosive liquids, be sure to take proper safety precautions, such as electrical grounding, inert atmosphere, etc.

TABLE 6 Chemical substance inventory status of AEROSIL® Pharma products

PRODUCT	AEROSIL® 200 Pharma	AEROSIL® 200 VV Pharma	AEROSIL® 300 Pharma	AEROPERL® 300 Pharma	AEROSIL® R 972 Pharma
CAS No.	112945-52-5 resp. 7631-86-9				68611-44-9
Chemical name	Silicon dioxide, chemically prepared				Silane, dichlorodi- methyl-, reaction products with silica
Australia AIIC	registered				registered
Canada DSL	registered				registered
China IECSC	registered				registered
Europe EINECS	231-545-4				271-893-4
Europe REACH	registered				registered
Europe C&L Inventory	notified				exempted
Japan ENCS	1-548				1-548/7-476
Korea KECI	KE-30953 (KE-31-032)				KE-10116
New Zealand NZIoC	registered				registered
Philippines PICCS	registered				registered
USA TSCA	registered				registered



REFERENCES

¹ see page 2

² Galenic considerations on AEROSIL® (in German) von Czetsch-Lindenwald, H. Die Pharmazie 12 (12) (1957) 589 - 592.

³ Galenic considerations on AEROSIL® II (in German) von Czetsch-Leisenwald, H, Die Pharmazie 12 (12) (1957) 810 - 811.

⁴ On direct compression of tablets (in German) Tawashi, R. Pharmazeutische Industrie 26 (1964) 682 - 685.

⁵ Option 1 offers the simplest way to show compliance with the ICH Q3D guideline. The option can be used for pharmaceutical preparations with daily dosage of 10 g or less. Table A2.2 list the limits of metals in each ingredient present in the preparation

⁶ Investigation of compacted hydrophilic and hydrophobic colloidal silicon dioxides as glidants for pharmaceutical excipients. Jonat, S., Hasenzahl, S., Drechsler, M., Albers, P., Wagner, K. W., Schmidt, P. C. Powder Technology, 141 (1-2) (2004) 31-43.

⁷ Investigation of the glidant properties of compacted colloidal silicon dioxide by angle of repose and X-ray photoelectron spectroscopy, Jonat, S., Albers, P., Gray, A., Schmidt, P.C., European Journal of Pharmaceutics and Biopharmaceutics 63 (2006) 356 – 359.

⁸ Granules on the basis of pyrogenic silica, process for their preparation and use thereof, European Patent EP 725037

⁹ Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions, European Patent EP 1439858

¹⁰ A. Wade, P. J. Weller (Eds.), Handbook of Pharmaceutical Excipients, 2nd Edition, American Pharmaceutical Association, Washington, The Pharmaceutical Press, London, 1994

¹¹ On the adsorption of drug substances on AEROSIL® in tablets (in German). Gstirner, E., Knipp, J. Pharmazeutische Industrie 24 (1962) 475-48 preparation and use thereof, European patent EP 725037Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions, European patent EP 1439858.

¹² The behavior of bacteria in highly pure silica acid (in German) Kienholz, M., Pharmazeutische Industrie, 32 (1970) 677-679

EUROPE / MIDDLE-EAST / AFRICA	AMERICAS	ASIA/PACIFIC
Evonik Operations GmbH Smart Effects business line Rodenbacher Chaussee 4 63457 Hanau Germany	Evonik Corporation Smart Effects business line 2 Turner Place Piscataway, NJ 08804 USA	Evonik Specialty Chemicals (Shanghai) Co., Ltd. Smart Effects business line 55 Chundong Road, Shanghai, China
ask-se@evonik.com www.evonik.com www.evonik.com/smarteffects	ask-se-americas@evonik.com	ask-se-asia@evonik.com

This information and any recommendations, technical or otherwise, are presented in good faith and believed to be correct as of the date prepared. Recipients of this information and recommendations must make their own determination as to its suitability for their purposes. In no event shall Evonik assume liability for damages or losses of any kind or nature that result from the use of or reliance upon this information and recommendations. EVONIK EXPRESSLY DISCLAIMS ANY REPRESENTATIONS AND WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, COMPLETENESS, NON-INFRINGEMENT, MERCHANTABILITY AND/OR FITNESS FOR A PARTICULAR PURPOSE (EVEN IF EVONIK IS AWARE OF SUCH PURPOSE) WITH RESPECT TO ANY INFORMATION AND RECOMMENDATIONS PROVIDED. Reference to any trade names used by other companies is neither a recommendation nor an endorsement of the corresponding product, and does not imply that similar products could not be used. Evonik reserves the right to make any changes to the information and/or recommendations at any time, without prior or subsequent notice.

AEROSIL® and **AEROPERL®** are registered trademarks of Evonik Industries AG or one of its subsidiaries.

The Silica and Silanes experts at Evonik – From elements to excellence.



www.evonik.com/smarteffects



evonik.click/smarteffects-health-care



Join us on **LinkedIn** to keep updated about our latest solutions, webinars and more